Clinical trials: Partial-Onset Seizures, open to volunteers
Seizures, Seizures, Focal
Study of the Pharmacokinetics, Safety, and Tolerability of ZONISADE in Children 1 Month to 17 Years of Age With Partial-onset Seizures
The purpose of this research is to determine the optimal dose, safety and tolerability of zonisamide oral suspension in children ages 1 month to 17 years of age who have partial-onset (focal) seizures.
- Conditions
- Seizures, Seizures, Focal, Seizure, Partial Onset, Seizure Disorder, Partial
- Trial name
- NCT06534502
- Testing
- Zonisamide Oral Product
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Azurity Pharmaceuticals
Partial-Onset Seizures, Primary Generalized Tonic-clonic Seizures
A Study to Evaluate the Safety of Fycompa Injection in Participants With Partial-Onset Seizures or Primary Generalized Tonic- Clonic Seizures
The purpose of this study is to determine the safety of Fycompa for injection after administration in participants with epilepsy (partial-onset seizures [including secondarily generalized seizures]) (age 4 years or older) or…
- Trial name
- NCT06657378
- Testing
- No Intervention
- Where
- Japan
- Volunteers
- 110 people
- Sponsor
- Eisai Co., Ltd.
Focal-Onset Seizures
Prospective Study of Eslicarbazepine in Adults With Focal-Onset Seizures
This prospective multicenter observational study will evaluate the effectiveness, safety, tolerability, and impact on quality of life of eslicarbazepine in adults with focal-onset seizures in routine clinical practice.
- Trial name
- ENGAGE (NCT07793396)
- Testing
- Eslicarbazepine acetate
- Where
- Pakistan
- Volunteers
- 1,500 people
- Sponsor
- King Edward Medical University
Partial Epilepsy
A Study to Evaluate the Safety, Efficacy, and PK of ONO-2017 in Japanese Patients With POS 2 to 17 Year Olds
Primary objective: To evaluate the safety and tolerability of cenobamate in Japanese pediatric subjects 2-17 years of age with partial-onset (focal) seizures
- Trial name
- NCT07594158
- Testing
- Cenobamate (tablet) for 12 to < 18 year olds, Cenobamate (syrup) for 2 to < 18 year olds
- Where
- Japan
- Volunteers
- 20 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Focal Epilepsy
Long-term Safety and Tolerability of BHV-7000
A study to determine if BHV- 7000 is safe and tolerable in adults with refractory focal onset epilepsy
- Trial name
- NCT06443463
- Testing
- BHV-7000
- Where
- 283 sites in United States, Argentina and 25 more
- Volunteers
- 660 people
- Sponsor
- Biohaven Therapeutics Ltd.
Focal Onset Seizures
RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults With Focal Onset Seizures
This is a Phase 2 double-blind, randomized, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy, safety, and tolerability of SPN-817 in adults with focal onset seizures.
- Trial name
- NCT06798896
- Testing
- SPN-817
- Where
- 63 sites in United States, Australia and 3 more
- Volunteers
- 216 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Focal Epilepsy, Epilepsy
A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures
This is a clinical research study for an investigational drug called RAP-219 in patients with Refractory Focal Epilepsy. This study is being conducted to determine RAP-219 Long- term safety and open-label antiseizure activity in…
- Conditions
- Focal Epilepsy, Epilepsy, Refractory Focal Epilepsy, Seizure
- Trial name
- NCT07219407
- Testing
- RAP-219
- Where
- 7 sites in United States
- Volunteers
- 30 people
- Sponsor
- Rapport Therapeutics Inc.
Epilepsies, Partial
Safety of Cenobamate in Japanese Subjects With Partial Onset Seizures
To evaluate the long-term safety and tolerability of cenobamate in Japanese epilepsy patients with partial seizures
- Trial name
- NCT06590896
- Testing
- Cenobamate
- Where
- 29 sites in Japan
- Volunteers
- 100 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Focal Onset Seizures
SPN-817 Open-Label Extension Study in Adults With Focal Onset Seizures
This is a Phase 2b open-label extension study to evaluate the long-term safety and efficacy of SPN-817.
- Trial name
- NCT07141329
- Testing
- SPN-817
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Supernus Pharmaceuticals, Inc.